Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry
Míriam Mañosa, A Fernández-Clotet, Pilar Nos, María Dolores Martín‐Arranz, Noemí Manceñido, Ana Yaiza Carbajo, Esther Hinojosa, Alejandro Hernández-Camba, Roser Muñoz-Pérez, Marta Maia Boscá-Watts, Marta Calvo, Mónica Sierra‐Ausín, E Sánchez-Rodríguez, Manuel Barreiro‐de Acosta, Alejandro Núñez-Alonso, Yamile Zabana, Lucía Márquez, Javier P. Gisbert, Jordi Guardiola, Empar Sáinz, Pedro Delgado‐Guillena, David Busquets, Manuel Van Domselaar, Eva Girona, Rufo Lorente, Diego Casas Deza, José María Huguet, Sergio Maestro, M. José Cabello, Jesús Castro, Marisa Iborra, Fiorella Cañete, Margalida Calafat, Eugeni Domènech
Topics & Concepts
VedolizumabMedicineUstekinumabCrohn's diseaseSurgeryInternal medicineDiseaseInfliximabInflammatory Bowel DiseaseAutoimmune and Inflammatory DisordersPlatelet Disorders and Treatments